Suzhou Biomissile Pharmaceuticals Co., Ltd.
2 clinical trials · Sponsor
◉ Watch Suzhou Biomissile Pharmaceuticals Co., Ltd.
| Record | Firm | Date |
|---|---|---|
| A Phase Ib/II Study of BM230 in Combination With PD-1 Inhibitor for HER2-related Advanced Solid Tumors (NCT07698587) | Suzhou Biomissile Pharmaceuticals Co., Ltd. | 2026-07-01 |
| Study of BM230 in Patients With Advanced Solid Tumors (NCT06644300) | Suzhou Biomissile Pharmaceuticals Co., Ltd. | 2024-12-16 |
Track Suzhou Biomissile Pharmaceuticals Co., Ltd. automatically
Every clearance here is in the API, with alerts when new ones post.